Stem Cells Transl Med. 2017 May;6(5):1312-1315. doi: 10.1002/sctm.17-0069.
Since the first successful allogeneic transplants performed in Seattle 50 years ago, the field of transplantation has evolved considerably, with improvements in human leukocyte antigen typing, patient selection, reduced intensity regimens, and graft-versus-host disease prophylaxis. A major breakthrough has been the availability of more donor options, first via the National Marrow Donor Program-Be the Match [Biol Blood Marrow Transplant 2008;14:2-7]. Then, in the 1990s, unrelated umbilical cord blood transplantation became available, first for children and then for adults [New Engl J Med 1996;35:157-166]. More recently mismatched unrelated transplants and haploidentical donor options became available [Blood 2011;118:282-288]. In 2017, there is a donor for almost every patient who needs a transplant. In this review, we will discuss the state of the science (and art) of cord blood transplant, focusing on successes, challenges, and future directions. Stem Cells Translational Medicine 2017;6:1312-1315.
自 50 年前西雅图首次成功进行同种异体移植以来，移植领域已经有了长足的发展，人类白细胞抗原分型、患者选择、降低强度方案和移植物抗宿主病预防等方面都有所改进。一个主要的突破是有了更多的供者选择，最初是通过国家骨髓捐赠者计划-成为匹配者[Biol Blood Marrow Transplant 2008;14:2-7]。然后，在 20 世纪 90 年代，非相关的脐带血移植开始可用，最初用于儿童，然后用于成人[New Engl J Med 1996;35:157-166]。最近，不匹配的非相关移植和半相合供者选择也成为可能[Blood 2011;118:282-288]。在 2017 年，几乎每一位需要移植的患者都有供者。在这篇综述中，我们将讨论脐带血移植的科学（和艺术）现状，重点讨论成功、挑战和未来方向。干细胞转化医学 2017;6:1312-1315。
